Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases

Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases

Bibliographic Details
Main Authors:	Jordi Remon, MD, María Castro-Henriques, Laura Esteller, Josep Vives
Format:	Article
Language:	English
Published:	Elsevier 2021-01-01
Series:	JTO Clinical and Research Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364320301429

Similar Items

Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial
by: Ashley M. Hopkins, et al.
Published: (2021-03-01)

Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial
by: Riad Salem, et al.
Published: (2021-08-01)

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
by: Ryo Toyozawa, MD, et al.
Published: (2020-03-01)

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
by: Breder, V., et al.
Published: (2022)

Addition of Anti-Angiogenetic Therapy with Bevacizumab to Chemo- and Radiotherapy for Leptomeningeal Metastases in Primary Brain Tumors.
by: Michael C Burger, et al.
Published: (2016-01-01)

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
by: Shukui Qin, et al.
Published: (2021-04-01)

Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
by: Ali AL Zahrani, et al.
Published: (2021-03-01)

Helical tomotherapy in patients with leptomeningeal metastases
by: Schiopu SRI, et al.
Published: (2018-12-01)

Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. <i>Cancers</i> 2021, <i>13</i>, 1176
by: Edouard Auclin, et al.
Published: (2021-07-01)

IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer
by: Stephen P. Hack, et al.
Published: (2021-07-01)

Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases
by: Emilie Le Rhun, et al.
Published: (2015-02-01)

Dural and Leptomeningeal Spine Metastases of Breast Cancer
by: Fernando Matos, et al.
Published: (2019-01-01)

How we treat patients with leptomeningeal metastases
by: Martin van den Bent, et al.
Published: (2019-05-01)

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
by: Chiun Hsu, et al.
Published: (2021-07-01)

Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC
by: I. А. Dzhanyan, et al.
Published: (2021-06-01)

Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
by: Masatoshi Kudo
Published: (2021-02-01)

Management of Brain and Leptomeningeal Metastases from Breast Cancer
by: Alessia Pellerino, et al.
Published: (2020-11-01)

A case report of endometrial adenocarcinoma with leptomeningeal metastases
by: Danial Fazilat‐Panah, et al.
Published: (2021-09-01)

Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. <i>Cancers</i> 2021, <i>13</i>, 1176”
by: Ashley M. Hopkins, et al.
Published: (2021-07-01)

Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases
by: Tian Y, et al.
Published: (2019-11-01)

A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab
by: Jiamao Lin, et al.
Published: (2021-06-01)

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
by: Jeffrey J. Wallin, et al.
Published: (2016-08-01)

A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy
by: Masatoshi Kudo
Published: (2020-03-01)

Erratum to “Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab”
Published: (2021-09-01)

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
by: Hideki Iwamoto, et al.
Published: (2021-06-01)

Prolonged response to atezolizumab with bevacizumab plus chemotherapy in a patient with lung cancer harboring mutation in EGFR after Afatinib treatment: A case report
by: Hayato Koba, et al.
Published: (2021-12-01)

Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis
by: I-Chun Chen, et al.
Published: (2016-04-01)

Bevacizumab in the treatment of NSCLC: patient selection and perspectives
by: Russo AE, et al.
Published: (2017-12-01)

Leptomeningeal Metastases in a Patient with an Extragonadal Germ Cell Tumor
by: Yoshiaki Kinebuchi M.D., et al.
Published: (2008-01-01)

Findings to Leptomeningeal Metastases in Lung Cancer: A Case Report
by: Thiago Rodrigo de Noronha, et al.
Published: (2019-01-01)

Focal Management of Large Brain Metastases and Risk of Leptomeningeal Disease
by: Samuel R. Marcrom, MD, et al.
Published: (2020-01-01)

Leptomeningeal Metastases in a Patient with Castration-Resistant Prostate Cancer
by: Takuya Koie, et al.
Published: (2020-01-01)

First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
by: Chi-Leung Chiang, et al.
Published: (2021-02-01)

Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature
by: Balraj Singh MD, et al.
Published: (2021-03-01)

301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study
by: Ralf Gutzmer, et al.
Published: (2020-11-01)

Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
by: Rachel Ryu, et al.
Published: (2018-07-01)

A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab
by: Wei Nie, et al.
Published: (2020-01-01)

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
by: Remon J, et al.
Published: (2019-05-01)

Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
by: Yuwa Ando, et al.
Published: (2021-08-01)

The Underlying Biology and Therapeutic Vulnerabilities of Leptomeningeal Metastases in Adult Solid Cancers
by: Matthew Dankner, et al.
Published: (2021-02-01)

Cannot write session to /tmp/vufind_sessions/sess_3brkn85gpe6sfnbe78tqk2phj6